Cancer Center, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, 530021, China.
Oncol Res. 2023 Jan 31;30(4):187-199. doi: 10.32604/or.2022.027534. eCollection 2022.
Nasopharyngeal carcinoma (NPC) is the most prevalent human primary malignancy of the head and neck, and the presence of vasculogenic mimicry (VM) renders anti-angiogenic therapy ineffective and poorly prognostic. However, the underlying mechanisms are unclear. In the present study, we used miR-940 silencing and overexpression for NPC cell EdU staining, wound healing assay and 3D cell culture assay, and xenograft mouse model and VM formation to assess miR-940 function. We found that ectopic miR-940 expression reduced NPC cell proliferation, migration and VM, as well as tumorigenesis . By bioinformatic analysis, circMAN1A2 was identified as a circRNA that binds to miR-940. Mechanistically, we confirmed that circMAN1A2 acts as a sponge for miR-940, impairs the inhibitory effect of miR-940 on target ERBB2, and then activates the PI3K/AKT/mTOR signaling pathway using RNA-FISH, dual luciferase reporter gene and rescue analysis assays. In addition, upregulation of ERBB2 expression is associated with clinical staging and poor prognosis of NPC. Taken together, the present findings suggest that circMAN1A2 promotes VM formation and progression of NPC through miR-940/ERBB2 axis and further activates the PI3K/AKT/mTOR pathway. Therefore, circMAN1A2 may become a biomarker and therapeutic target for anti-angiogenic therapy in patients with nasopharyngeal carcinoma.
鼻咽癌(NPC)是头颈部最常见的原发性恶性肿瘤,血管生成拟态(VM)的存在使抗血管生成治疗无效且预后不良。然而,其潜在机制尚不清楚。在本研究中,我们使用 miR-940 沉默和过表达进行 NPC 细胞 EdU 染色、划痕愈合实验和 3D 细胞培养实验,以及异种移植小鼠模型和 VM 形成来评估 miR-940 的功能。我们发现异位 miR-940 表达降低 NPC 细胞增殖、迁移和 VM 以及肿瘤发生。通过生物信息学分析,鉴定出 circMAN1A2 是一种与 miR-940 结合的 circRNA。在机制上,我们证实 circMAN1A2 作为 miR-940 的海绵,破坏 miR-940 对靶标 ERBB2 的抑制作用,然后使用 RNA-FISH、双荧光素酶报告基因和挽救分析实验激活 PI3K/AKT/mTOR 信号通路。此外,ERBB2 表达上调与 NPC 的临床分期和预后不良相关。综上所述,本研究结果表明,circMAN1A2 通过 miR-940/ERBB2 轴促进 NPC 的 VM 形成和进展,并进一步激活 PI3K/AKT/mTOR 通路。因此,circMAN1A2 可能成为鼻咽癌抗血管生成治疗的生物标志物和治疗靶点。
Artif Cells Nanomed Biotechnol. 2019-12
Clin Med Insights Oncol. 2024-6-6
Am J Cancer Res. 2023-12-15
Cell Death Dis. 2022-4-28
Front Oral Health. 2021-3-31
Transl Lung Cancer Res. 2021-11
Nat Rev Clin Oncol. 2022-3
Mol Ther Nucleic Acids. 2021-5-8